Expression of CD44, EGFR, p16, and their mutual combinations in
patients with head and neck cancer: Impact on outcomes of
intensity-modulated radiation therapy

J 2019

Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy

SLÁVIK, Marek, Tetiana SHATOKHINA, Jiří ŠÁNA, Parwez AHMAD, Tomáš KAZDA et. al.

Basic information

Original name

Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy

Authors

SLÁVIK, Marek (703 Slovakia, belonging to the institution), Tetiana SHATOKHINA (804 Ukraine, belonging to the institution), Jiří ŠÁNA (203 Czech Republic, belonging to the institution), Parwez AHMAD (356 India, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Iveta SELINGEROVÁ (203 Czech Republic, belonging to the institution), Markéta HERMANOVÁ (203 Czech Republic, belonging to the institution), Renata ČERVENÁ (203 Czech Republic, belonging to the institution), Tomáš NOVOTNÝ (203 Czech Republic), Petr BURKOŇ (203 Czech Republic, belonging to the institution), Pavel SMILEK (203 Czech Republic, belonging to the institution), Zuzana HORÁKOVÁ (203 Czech Republic, belonging to the institution), Pavel ŠLAMPA (203 Czech Republic, guarantor, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, belonging to the institution)

Edition

Head and Neck, Hoboken, Wiley, 2019, 1043-3074

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30206 Otorhinolaryngology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.538

RIV identification code

RIV/00216224:14110/19:00108450

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/hed.25533

UT WoS

000461866800016

Keywords in English

CD44; EGFR; immunohistochemistry; intensity-modulated radiotherapy; P16

Abstract

V originále

Background Progress in radiation treatment of head and neck squamous cell carcinoma (HNSCC) deserves the studies focused on molecular predictors that would help to enhance individually tailored treatment. Methods p16/epidermal growth factor receptor (EGFR)/cluster of differentiation-44 (CD44) was immunohistochemically analyzed in 165 HNSCC patients. Results In the entire group and the p16 negative cohort, better 3-year overall survival and locoregional control correlated with p16 positivity, CD44, and EGFR negativity were observed. Combined analysis revealed the worst results in the CD44+/p16-, EGFR+/p16-, and EGFR+/CD44+ groups and in the EGFR+/CD44+ within p16 negative cohort. Multivariate analysis found tumor stage, Karnofsky index, p16, and CD44 as prognostic factors of overall survival and clinical stage, and p16 as a prognostic factor for locoregional control. Clinical stage and Karnofsky index affected overall survival and tumor stage. EGFR affected locoregional control in the p16 negative subgroup. Conclusion Our study confirmed the negative effect of CD44 and EGFR and the positive effect of p16 on radiotherapy results.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

NV15-31627A, research and development project

Name: Možnosti molekulárně řízené radikální radioterapie nebo radiochemoterapie dle profilu mikroRNA u pacientů se spinocelulárními karcinomy hlavy a krku.

Citovat

SLÁVIK, Marek, Tetiana SHATOKHINA, Jiří ŠÁNA, Parwez AHMAD, Tomáš KAZDA, Iveta SELINGEROVÁ, Markéta HERMANOVÁ, Renata ČERVENÁ, Tomáš NOVOTNÝ, Petr BURKOŇ, Pavel SMILEK, Zuzana HORÁKOVÁ, Pavel ŠLAMPA and Ondřej SLABÝ. Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy. Head and Neck. Hoboken: Wiley, 2019, vol. 41, No 4, p. 940-949. ISSN 1043-3074. Available from: https://dx.doi.org/10.1002/hed.25533.

@article{1497636,
   author = {Slávik, Marek and Shatokhina, Tetiana and Šána, Jiří and Ahmad, Parwez and Kazda, Tomáš and Selingerová, Iveta and Hermanová, Markéta and Červená, Renata and Novotný, Tomáš and Burkoň, Petr and Smilek, Pavel and Horáková, Zuzana and Šlampa, Pavel and Slabý, Ondřej},
   article_location = {Hoboken},
   article_number = {4},
   doi = {http://dx.doi.org/10.1002/hed.25533},
   keywords = {CD44; EGFR; immunohistochemistry; intensity-modulated radiotherapy; P16},
   language = {eng},
   issn = {1043-3074},
   journal = {Head and Neck},
   title = {Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy},
   url = {http://dx.doi.org/10.1002/hed.25533},
   volume = {41},
   year = {2019}
}

TY  - JOUR
ID  - 1497636
AU  - Slávik, Marek - Shatokhina, Tetiana - Šána, Jiří - Ahmad, Parwez - Kazda, Tomáš - Selingerová, Iveta - Hermanová, Markéta - Červená, Renata - Novotný, Tomáš - Burkoň, Petr - Smilek, Pavel - Horáková, Zuzana - Šlampa, Pavel - Slabý, Ondřej
PY  - 2019
TI  - Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy
JF  - Head and Neck
VL  - 41
IS  - 4
SP  - 940-949
EP  - 940-949
PB  - Wiley
SN  - 10433074
KW  - CD44
KW  - EGFR
KW  - immunohistochemistry
KW  - intensity-modulated radiotherapy
KW  - P16
UR  - http://dx.doi.org/10.1002/hed.25533
L2  - http://dx.doi.org/10.1002/hed.25533
N2  - Background Progress in radiation treatment of head and neck squamous cell carcinoma (HNSCC) deserves the studies focused on molecular predictors that would help to enhance individually tailored treatment. Methods p16/epidermal growth factor receptor (EGFR)/cluster of differentiation-44 (CD44) was immunohistochemically analyzed in 165 HNSCC patients. Results In the entire group and the p16 negative cohort, better 3-year overall survival and locoregional control correlated with p16 positivity, CD44, and EGFR negativity were observed. Combined analysis revealed the worst results in the CD44+/p16-, EGFR+/p16-, and EGFR+/CD44+ groups and in the EGFR+/CD44+ within p16 negative cohort. Multivariate analysis found tumor stage, Karnofsky index, p16, and CD44 as prognostic factors of overall survival and clinical stage, and p16 as a prognostic factor for locoregional control. Clinical stage and Karnofsky index affected overall survival and tumor stage. EGFR affected locoregional control in the p16 negative subgroup. Conclusion Our study confirmed the negative effect of CD44 and EGFR and the positive effect of p16 on radiotherapy results.
ER  -

SLÁVIK, Marek, Tetiana SHATOKHINA, Jiří ŠÁNA, Parwez AHMAD, Tomáš KAZDA, Iveta SELINGEROVÁ, Markéta HERMANOVÁ, Renata ČERVENÁ, Tomáš NOVOTNÝ, Petr BURKOŇ, Pavel SMILEK, Zuzana HORÁKOVÁ, Pavel ŠLAMPA and Ondřej SLABÝ. Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy. \textit{Head and Neck}. Hoboken: Wiley, 2019, vol.~41, No~4, p.~940-949. ISSN~1043-3074. Available from: https://dx.doi.org/10.1002/hed.25533.

Detailed Information on Publication Record